Key result
EACA effectively controls bleeding but carries a notable risk of widespread thrombi.
Why the study?
Epsilon-aminocaproic acid (EACA) is the only potent antifibrinolytic agent commercially available in the US with claimed efficacy in various bleeding conditions but with uncertain thrombotic risk.
Comparison
EACA administration via oral or intravenous routes versus no antifibrinolytic or other treatments
Design
Review
Authors
Loading...
EACA's pharmacokinetics enable flexible dosing for bleeding; leaves open its role versus modern alternatives in current guidelines.
EACA is an effective antifibrinolytic for controlling bleeding in various clinical scenarios, but carries significant risks of thrombosis, hypotension, arrhythmias, and rhabdomyolysis.
Griffin et al. (2008) conducted a review in Bleeding. Epsilon-Aminocaproic Acid (EACA) was evaluated. Epsilon-aminocaproic acid (EACA) is an effective antifibrinolytic agent for controlling bleeding, but its potential benefits must be weighed against serious complications such as widespread thrombi.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: